{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dy GK"],"funding":["NCI NIH HHS"],"pagination":["3311-3317"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10414711"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(18)"],"pubmed_abstract":["<i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>In the longest follow-up, to our knowledge, for a KRAS<sup>G12C</sup> inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with <i>KRAS</i> G12C-mutated advanced non-small-cell lung cancer (NSCLC) from the CodeBreaK 100 clinical trial (ClinicalTrials.gov identifier: NCT03600883). This multicenter, single-group, open-labe"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100."],"pmcid":["PMC10414711"],"funding_grant_id":["R01 CA230745","P30 CA008748","P30 CA138292","P01 CA129243","R01 CA279264","R01 CA230267"],"pubmed_authors":["Sacher AG","Hindoyan A","Addeo A","Lito P","Anderson A","Desai J","Hong DS","Tomasini P","Li BT","Dooms C","Italiano A","Snyder W","Kim DW","Takahashi T","Ramalingam SS","Govindan R","Tran Q","Skoulidis F","Falchook GS","Wolf J","Dy GK","Schuler M","Jones S","Velcheti V"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.","description":"<i>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in</i> JCO <i>or elsewhere, for which the primary end point has already been reported.</i>In the longest follow-up, to our knowledge, for a KRAS<sup>G12C</sup> inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with <i>KRAS</i> G12C-mutated advanced non-small-cell lung cancer (NSCLC) from the CodeBreaK 100 clinical trial (ClinicalTrials.gov identifier: NCT03600883). This multicenter, single-group, open-labe","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-05-29T19:15:29.769Z","creation":"2024-11-05T19:25:05.85Z"},"accession":"S-EPMC10414711","cross_references":{"pubmed":["37098232"],"doi":["10.1200/JCO.22.02524"]}}